Pancreatic Diseases clinical trials

The registry lists 184 studies for Pancreatic Diseases across more than 10 countries. 63 are recruiting or about to start. 65 of them are mainly about Pancreatic Diseases (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-05. Counting its 24 narrower conditions too, such as Pancreatic Neoplasms: 6,873 studies, 1,566 open.

Get an email when these change. Save the Pancreatic Diseases studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed: 78
Recruiting: 43
Status unknown: 24
Not yet recruiting: 18
Terminated: 9
Withdrawn: 5

Phase

Phase 2: 24
Phase 3: 15
Phase 4: 8
Phase 1: 7

Where

United States: 60
China: 23
Italy: 21
Canada: 17
France: 16
United Kingdom: 12

Who runs them

IRCCS San Raffaele (8) · Changhai Hospital (7) · Vertex Pharmaceuticals Incorporated (5) · Stanford University (3) · Second Affiliated Hospital, School of Medicine, Zhejiang University (3) · Memorial Sloan Kettering Cancer Center (3) · Indiana University (3) · Ruijin Hospital (3)

What is being tested here

Drugs under test in Pancreatic Diseases studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Open	Phase 3	All
Dabrafenib	1	1	1
Trametinib	1	1	1
Ondansetron	1	1	1
Paclitaxel	0	1	5
Ivacaftor	0	2	4
Albumin-Bound Paclitaxel	0	1	3
Ersodetug	0	1	2
Gemcitabine	0	0	2
Submicron Particle Paclitaxel Sterile Suspension	0	0	2
MK-4721	0	0	2

Drug classes tested here Antimitotic agents 5

Coming up

3phase 3 studies under way

22studies finish main data collection within a year1 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Dec 2026Evaluating the Safety and Efficacy of Ondansetron in the Prevention of Post Endoscopic Retrograde Cholangiopancreatography Pancreatitis · Phase 3 · Tanta University
Nov 2026Development and Prospective Validation of an AI-Based Diagnostic Model for Hepato-Pancreato-Biliary Diseases · Second Affiliated Hospital, School of Medicine, Zhejiang University
Dec 2026The Effects of the CF Carrier State on the Kidneys and Pancreas · Philip Polgreen
Dec 2026Artificial Intelligence in Endoscopic Ultrasound · Orlando Health, Inc.
Dec 2026Nurse-Led Education Before ERCP: Effects on Patient Knowledge and Anxiety · Gazi University
Dec 2026Feasibility and Effectiveness of Three-day Discharge After Distal Pancreatectomy · IRCCS San Raffaele
Dec 2026Integration of Multiomics Markers for Invasive IPMNs Identification Through the Set-up of the INvasive Cyst bIomarkers Detection (INCITE) Consortium · IRCCS San Raffaele
Dec 2026Early Diagnosis of Pancreatic Cancer Duodenal Fluid-Based Biomarker Exploratory Study · Do Hyun Park
Mar 2027Radiology Registry on Pancreatic Malignancies · IRCCS San Raffaele
Mar 2027STTEPP: Safety, Tolerability and Dose Limiting Toxicity of Lacosamide in Patients With Painful Chronic Pancreatitis · Indiana University

Who these studies take

Of the 43 Pancreatic Diseases studies recruiting now, 25 (58%) set no upper age limit and 4 (9%) stop at 75 or younger. 7 (16%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 8 (19%) take healthy volunteers.

Recruiting studies that take each age, of 43
Age	Women	Men
10	5 (12%)	5 (12%)
18	41 (95%)	41 (95%)
30	41 (95%)	41 (95%)
40	41 (95%)	41 (95%)
50	41 (95%)	41 (95%)
65	41 (95%)	41 (95%)
75	40 (93%)	40 (93%)
85	36 (84%)	36 (84%)

Across all 184 studies, recruiting or not: 10% stop at 75 or younger and 7% at 65; 21% take children; 0% are for women only and 1% for men only; 13% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Pancreatic Diseases studies take

Of 44 observational studies under Pancreatic Diseases, half reached primary completion within 67 months of starting, counting those still running.

Start to primary completion	Every sponsor	Industry	Non-industry
Interventional, no phase	35 mo20–44 · 32 studies	—	—
Observational	67 mo22–119 · 44 studies	—	—

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 14, 2026.

Started recruiting1

Feasibility and Effectiveness of Three-day Discharge After Distal PancreatectomyNov 5, 2026NCT07095621

Newly registered1

Histotripsy x Pancreatic CancerOct 14, 2026NCT07873606

Studies

Recruiting first, then most recently updated. Showing 50 of 184. Browse all 184 → or search them.